E4512 ALCHEMIST ALK+ A Phase III early stage NSCLC Crizotinib vs Observation Research Question:
Does the drug crizotinib treat patients with non-small cell lung cancer?
Basic Study Information
Purpose:Location: Highland Hospital
This randomized phase III trial studies how well crizotinib works in treating patients
with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and
has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or
changes, in ALK can make it very active and important for tumor cell growth and progression.
Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working.
Crizotinib may be an effective treatment for patients with non-small cell lung cancer
and an ALK fusion mutation.
Lead Researcher (Principal Investigator)
Study Contact Information
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search